Proud to announce the launch of Meliora Therapeutics, a mechanism-focused drug development company, co-founded with David Li and Joan Smith, with $11M in seed funding from HOF Capital, Obvious Ventures, @Zhenfund, Village Global, and others. wsj.com/articles/biote…

1/ I'm thrilled to share what we've been working on for the past year Meliora Therapeutics ! Meliora believes the future of oncology drug development will be mechanism based. melioratx.com

8/ Thank you The Wall Street Journal for covering our launch today! wsj.com/articles/biote…

Today ⁦Meliora Therapeutics⁩ came out from the stealth with an announcement of $11M seed round. We are proud to back such a visionary team ⁦David Li⁩ ⁦Jason Sheltzer⁩ @Joans with incredible investors ⁦HOF Capital⁩ ⁦ZhenFund⁩ ⁦and others businesswire.com/news/home/2022…

Congrats David Li and the Meliora Therapeutics team!

Congratulations to David Li and team!

Exclusive look at the pitch deck Meliora Therapeutics used to raise its $11 million seed round to find and develop better cancer treatments through its ML/AI tech platform businessinsider.com/meliora-therap…

Founder Spotlight 🔬: David Li @ Meliora Therapeutics Learn more about David Li & the creation of Meliora Therapeutics below... ow.ly/w91050L6vzh

I just posted part 2 of the article "Machine learning-powered drug discovery: Now and Tomorrow" in my newsletter. ouncebiotech.substack.com/p/machine-lear…

Meliora Tx is committed to bringing a new approach to oncology drug dev. This example from Jason Sheltzer's lab demonstrates why identifying drug MOA's at scale is incredibly powerful - and necessary!

Very excited to welcome Claudio Chuaqui as our new SVP, Head of Drug Discovery at Meliora. Please read more here: businesswire.com/news/home/2023…